Story perspectives

Opus Genetics Launches Trial for Night Driving Vision Aid

9/11/2025

47 11

Summary

Story summary

Opus Genetics has launched the LYNX-3 trial to evaluate phentolamine ophthalmic solution 0.75% for night driving impairment in keratorefractive patients.
The trial aims to enroll around 200 adults with reduced mesopic vision after LASIK or PRK surgery.
Participants will receive phentolamine or a placebo for two weeks, targeting a >=15-letter improvement in visual acuity.
Previous trials, LYNX-1 and LYNX-2, indicated phentolamine's effectiveness in enhancing low-contrast vision.
Results from LYNX-3 are anticipated by March 2026, with interim data potentially available earlier.

1 of 1

Story summary

Opus Genetics has launched the LYNX-3 trial to evaluate phentolamine ophthalmic solution 0.75% for night driving impairment in keratorefractive patients.
The trial aims to enroll around 200 adults with reduced mesopic vision after LASIK or PRK surgery.
Participants will receive phentolamine or a placebo for two weeks, targeting a >=15-letter improvement in visual acuity.
Previous trials, LYNX-1 and LYNX-2, indicated phentolamine's effectiveness in enhancing low-contrast vision.
Results from LYNX-3 are anticipated by March 2026, with interim data potentially available earlier.